| 产品描述: | M4284 is a selective and orally active biphenyl mannoside FimH antagonist. M4284 has activities against different UPEC (Urinary tract infections (UTI) caused by uropathogenic E. coli) strains in different host genetic backgrounds and gut microbial community contexts |
| 靶点: |
IC50: FimH |
| 体内研究: |
M4284 (oral administration; 100 mg/kg; 3 doses) can reduces UTI89 levels in the gut and urinary tracts of mice that are concurrently colonized with UTI89 in the gut and bladder. And treating mice with additonal M4284 doses further reduces the UTI89 population and the number of UPEC is lower in M4284-treated mice after termination of treatment. Animal Model: C3H/HeN mice. Dosage: 100 mg/kg Administration: Oral administation; a single dose. Result: Had activities against different UPEC strains in different host genetic backgrounds and gut microbial community contexts. |
| 参考文献: |
1. Schaeffer EM, et al.Selective Depletion of Uropathogenic E. coli from the Gut by a FimH Antagonist.SelectivJ Urol. 2018 Apr;199(4):874-875. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.172 ml |
10.858 ml |
21.716 ml |
| 5 mM |
0.434 ml |
2.172 ml |
4.343 ml |
| 10 mM |
0.217 ml |
1.086 ml |
2.172 ml |
| 50 mM |
0.043 ml |
0.217 ml |
0.434 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |